Drug Patents owned by Janssen Biotech

1. List of Balversa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8895601 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors
May, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9464071 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors
Apr, 2031

(8 years from now)

US9902714 JANSSEN BIOTECH Quinoxaline derivatives useful as FGFR kinase modulators
Mar, 2035

(12 years from now)

US10898482 JANSSEN BIOTECH Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
Feb, 2036

(13 years from now)

US11077106 JANSSEN BIOTECH Cancer treatment
Feb, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 12, 2024

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: April, 2023

Market Authorisation Date: 12 April, 2019

Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic, surgically unresectable urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 or fgfr2 genetic alterations, and progressed during or following prior platinum-containing chemotherapy, with dosing based on serum phosphate levels

Dosage: TABLET;ORAL

More Information on Dosage

2. List of Erleada drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9388159 JANSSEN BIOTECH Substituted diazaspiroalkanes as androgen receptor modulators
Mar, 2027

(4 years from now)

US8445507 JANSSEN BIOTECH Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Sep, 2030

(7 years from now)

US9481663 JANSSEN BIOTECH Crystalline forms of an androgen receptor modulator
Jun, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987261 JANSSEN BIOTECH Substituted diazaspiroalkanes as androgen receptor modulators
Mar, 2027

(4 years from now)

US8802689 JANSSEN BIOTECH Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Mar, 2027

(4 years from now)

US9884054 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(10 years from now)

US10052314 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(10 years from now)

US10849888 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(10 years from now)

US10702508 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
Apr, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 14, 2023
New Indication (I) Sep 17, 2022

Drugs and Companies using APALUTAMIDE ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 14 February, 2018

Treatment: Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment of metastatic castration-sensitive prostate cancer (mcspc); Treatment in combination with a gnrh agonist of non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment in combination with a gnrh agonist of high risk non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment in combination with orchiectomy of non-metastatic, castration-resistant prostate cancer (nmcrpc); Treatment in combination with androgen deprivation therapy of non-metastatic, castration-resistant prostate cancer (nmcrpc) that improves metastasis free survival

Dosage: TABLET;ORAL

How can I launch a generic of ERLEADA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic